MX2010003441A - Formulaciones galenicas de alisquireno y valsartan. - Google Patents

Formulaciones galenicas de alisquireno y valsartan.

Info

Publication number
MX2010003441A
MX2010003441A MX2010003441A MX2010003441A MX2010003441A MX 2010003441 A MX2010003441 A MX 2010003441A MX 2010003441 A MX2010003441 A MX 2010003441A MX 2010003441 A MX2010003441 A MX 2010003441A MX 2010003441 A MX2010003441 A MX 2010003441A
Authority
MX
Mexico
Prior art keywords
minutes
organic compounds
galenical formulations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2010003441A
Other languages
English (en)
Inventor
Stefan Hirsch
Shoufeng Li
Nicoletta Loggia
James Kowalski
Marie-Christine Wolf
Wei-Qin Tong
Jay Parthiban Lakshman
Indrajit Ghosh
Sudha Vippagunta
Catherine Curdy
Ralf Altenburger
Maggy Babiole Saunier
Nicole Bargenda
Michaela Anna Maria Bock
Sabine Adler
Bruno Buss
Patrice Francois Keller
Charu Kochhar
Amol Singh Matharu
Julien Taillemite
Hong Wen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003441(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010003441A publication Critical patent/MX2010003441A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invenci?n se refiere a una combinaci?n farmac?utica de dosis oral fija, la cual comprende: a) una cantidad terap?uticamente efectiva de Alisquireno, o una sal farmac?uticamente aceptable del mismo, b) una cantidad terap?uticamente efectiva de Valsartan, o una sal farmac?uticamente aceptable del mismo, en donde la combinaci?n farmac?utica de dosis oral fija muestra una disoluci?n in vitro del componente a) del 80 por ciento o menos despu?s de 10 minutos, y del 98 por ciento o menos despu?s de 20 minutos, y un perfil de disoluci?n del componente b) del 25 por ciento o m?s despu?s de 30 minutos, y del 40 por ciento o m?s despu?s de 60 minutos, a un pH de 4.5.
MX2010003441A 2007-09-28 2008-09-24 Formulaciones galenicas de alisquireno y valsartan. MX2010003441A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97590107P 2007-09-28 2007-09-28
US97590907P 2007-09-28 2007-09-28
US97591907P 2007-09-28 2007-09-28
US97592507P 2007-09-28 2007-09-28
PCT/US2008/077416 WO2009045795A2 (en) 2007-09-28 2008-09-24 Galenical formulations of aliskiren and valsartan

Publications (1)

Publication Number Publication Date
MX2010003441A true MX2010003441A (es) 2010-04-21

Family

ID=40377183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003441A MX2010003441A (es) 2007-09-28 2008-09-24 Formulaciones galenicas de alisquireno y valsartan.

Country Status (18)

Country Link
US (1) US20100209480A1 (es)
EP (1) EP2205233A2 (es)
JP (1) JP2010540547A (es)
KR (1) KR20100063090A (es)
CN (1) CN101808631A (es)
AR (1) AR066168A1 (es)
AU (1) AU2008309058B2 (es)
BR (1) BRPI0817442A2 (es)
CA (1) CA2698330A1 (es)
CL (1) CL2008002829A1 (es)
CO (1) CO6270217A2 (es)
EC (1) ECSP10010052A (es)
MA (1) MA31706B1 (es)
MX (1) MX2010003441A (es)
PE (1) PE20090654A1 (es)
TN (1) TN2010000135A1 (es)
TW (1) TW200924737A (es)
WO (1) WO2009045795A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091203A1 (es) * 2007-09-28 2009-09-11 Novartis Ag Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
US20120009257A1 (en) * 2009-03-20 2012-01-12 Indrajit Ghosh Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren
KR20110129482A (ko) * 2009-03-20 2011-12-01 노파르티스 아게 알리스키렌을 포함하는 제약 조성물
TW201136582A (en) * 2010-03-16 2011-11-01 Novartis Ag Improved pharmaceutical compositions of aliskiren and methods of delivery
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
WO2013055668A1 (en) * 2011-10-12 2013-04-18 Dow Global Technologies Llc Injection-molded dosage form
WO2013098268A2 (en) * 2011-12-26 2013-07-04 Novartis Ag Tablets and dry-coated agents
CN103349652B (zh) * 2013-05-11 2014-11-19 辽宁大学 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
BRPI0516128A (pt) * 2004-10-08 2008-08-26 Novartis Ag uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
CN101166523A (zh) * 2005-04-27 2008-04-23 诺瓦提斯公司 治疗动脉粥样硬化的方法

Also Published As

Publication number Publication date
PE20090654A1 (es) 2009-06-27
WO2009045795A3 (en) 2009-07-16
ECSP10010052A (es) 2010-04-30
AU2008309058B2 (en) 2012-08-09
AU2008309058A1 (en) 2009-04-09
TN2010000135A1 (en) 2011-09-26
JP2010540547A (ja) 2010-12-24
CA2698330A1 (en) 2009-04-09
WO2009045795A2 (en) 2009-04-09
BRPI0817442A2 (pt) 2015-06-16
TW200924737A (en) 2009-06-16
MA31706B1 (fr) 2010-09-01
CO6270217A2 (es) 2011-04-20
CL2008002829A1 (es) 2009-06-26
CN101808631A (zh) 2010-08-18
EP2205233A2 (en) 2010-07-14
KR20100063090A (ko) 2010-06-10
AR066168A1 (es) 2009-07-29
US20100209480A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
TN2010000135A1 (en) Galenical formulations of organic compounds
PT2205279E (pt) Associação farmacêutica de aliscireno e valsartan
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
ZA200806778B (en) N-Hydroxyacrylamide compounds
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
IL187632A (en) 17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
JO3239B1 (ar) تركيبات جالينية من مركبات عضوية
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
TN2010000120A1 (en) Galenical formulations of organic compounds
MX2009005804A (es) Composicion farmaceutica de memantina.
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
TN2011000100A1 (en) Galenical formulations of organic compounds
MX2011009846A (es) Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
ZA201005394B (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative
TW200833375A (en) Pharmaceutical compositions
WO2010027189A3 (ko) 호모아이소플라베논 또는 이의 염의 신규한 용도
WO2010044108A3 (en) Controlled release formulations of ropinirole

Legal Events

Date Code Title Description
FA Abandonment or withdrawal